Search
for
Sort by
Research 91–120 of 1000+
- Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
- Alopecia universalis successfully treated with tofacitinib
- Efficacy of tofacitinib in pediatric alopecia universalis
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Baricitinib Induced Hypoglycemic Seizures in a Patient with Hair Loss and Type I Diabetes Mellitus: A Case Report
- Possible Involvement of Skin‐Resident Memory T Cells in Refractory Chronic Alopecia Areata
- 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo
- Abstracts from the 2024 WDS Forum - virtual option
- Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia
- Advances in the mechanism and new therapies of alopecia areata
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Citrullination at the Inflammatory Skin Barrier
- Baricitinib Attenuates IFN-γ and Polyinosinic:polycytidylic Acid‒Induced Mitochondrial Damage and Inflammasome Activation in Human Keratinocytes
- Medical Therapies
- Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
- Novel TMEM173 Mutation and the Role of Disease Modifying Alleles
- Baricitinib: From Rheumatoid Arthritis to COVID‐19
- STAT5 Activation in the Dermal Papilla Is Important for Hair Follicle Growth Phase Induction
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
- Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study
- Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
- Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- 056 IL-15 prolongs hair growth and operates as a guardian of human hair follicle immune privilege
- Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications